Ardelyx (ARDX) vs Monte Rosa Therapeutics (GLUE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Monte Rosa Therapeutics (GLUE) has outperformed Ardelyx (ARDX) over the past year, gaining 33.9% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with -51.3% for GLUE. Monte Rosa Therapeutics is the larger company by market cap ($880.4 million vs $844.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | GLUE |
|---|---|---|
| Share price | $3.27 | $10.32 |
| Market cap | $844.27M | $880.43M |
| 1-day change | +0.31% | +1.47% |
| YTD return | -43.91% | -34.18% |
| 1-year return | -35.38% | +33.85% |
| 5-year return | +202.78% | -51.32% |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $25.77 |
| 52-week low | $3.18 | $8.53 |
| Distance from 52-week high | -61.07% | -59.95% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +294.50% | +171.32% |
| Average volume | 4.17M | 1.33M |
| Shares outstanding | 258.19M | 85.31M |
| Employees | 489 | 173 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GLUE has outperformed ARDX by 69.2 percentage points over the past year.
- The two companies sit in different sectors: Ardelyx in Healthcare and Monte Rosa Therapeutics in Health Care.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About Monte Rosa Therapeutics
GLUE stock →Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 173 employees
ARDX vs GLUE FAQ
Which is bigger, Ardelyx or Monte Rosa Therapeutics?
Monte Rosa Therapeutics (GLUE) is larger, with a market capitalization of $880.43M compared with $844.27M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or GLUE?
GLUE returned +33.85% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Monte Rosa Therapeutics in the same industry?
No. Ardelyx is in the Healthcare sector, while Monte Rosa Therapeutics is in Health Care.